BTIG analyst David Larsen has maintained their neutral stance on AGL stock, giving a Hold rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Larsen has given his Hold rating due to a combination of factors influencing Agilon Health’s current financial outlook. The company reported higher-than-expected revenue growth for the fourth quarter of 2024, but its adjusted EBITDA fell short of expectations. Furthermore, the guidance for 2025 indicates lower revenue and medical margin estimates compared to prior projections, suggesting a challenging financial environment ahead.
Despite these challenges, Agilon Health is taking strategic steps to mitigate risks and improve financial discipline. The company is actively reducing its exposure to high-cost areas like Medicare Part D and is repricing its membership to better align with market conditions. Additionally, Agilon Health is exiting unprofitable programs and focusing on a disciplined growth strategy, which includes managing downside risks and preparing for potential improvements in 2026. These efforts, while promising, suggest a cautious approach, justifying the Hold rating as the company navigates through a transitional period.